532
Participants
Start Date
September 1, 2016
Primary Completion Date
September 1, 2018
Study Completion Date
September 1, 2018
ExoDx Prostate Intelliscore
ExoDx Prostate (IntelliScore) is a non-invasive, urinary 3-gene expression validated test in which the results of the assay are adjunctive to the ordering physician's clinical judgment and work-up of the patient in the determination of whether a prostate needle biopsy is necessary. The ExoDx Prostate (IntelliScore) was clinically validated to discriminate patients with higher grade prostate cancer from those with more indolent lower grade cancer and benign disease.
Manhattan Medical Research, New York
NYU Urology Associates, New York
Icahn School of Medicine at Mount Sinai, New York
Columbia University Medical Center, New York
Walter Reed National Military Medical CPDR, Bethesda
Johns Hopkins University, Baltimore
Urology of Virginia, Virginia Beach
Associated Urologists of North Carolina, Raleigh
Carolina Urologic Research Center, Myrtle Beach
Southeastern Urology Associates, Macon
Mount Sinai Medical Center of Florida, Miami
21st Century Oncology, Fort Myers
Comprehensive Urology, Royal Oak
Five Valley Urology, Missoula
UT Health Science Center, San Antonio
Premier Urology Group, Edison
Urologic Research and Consulting LLC, Englewood
Delaware Valley Urology, Voorhees Township
Lead Sponsor
Exosome Diagnostics, Inc.
INDUSTRY